AstraZeneca: positive results in ovarian cancer for Lynparza

(CercleFinance.com) - Lynparza, which is being jointly developed by AstraZeneca and Merck, showed positive interim results in a phase III study with patients with ovarian cancer, the companies said on Wednesday.


Women with BRCA-mutated (BRCAm) advanced ovarian cancer treated 1st-line with Lynparza tablets had a statistically-significant and clinically-meaningful improvement in progression-free survival compared to placebo, the trial showed.

Based upon these data, AstraZeneca and Merck plan to initiate discussions with health authorities regarding regulatory submissions.

In 2017, AstraZeneca and Merck signed a global strategic collaboration in oncology to jointly develop and market Lynparza, a cancer cell killer, for multiple types of cancer.

Copyright (c) 2018 CercleFinance.com. All rights reserved.